We investigated the effects of endogenous neurotrophin signaling on the death-survival of immature retinal ganglion cells (RGCs) in vivo. Null mutation of brain-derived neurotrophic factor [(BDNF) alone or in combination with neurotrophin 4 (NT4)] increases the peak rate of developmental RGC death as compared with normal. Null mutation of NT4 alone is ineffective. Null mutation of the full-length trkB (trkB FL ) receptor catalytic domain produces a dose-dependent increase in the peak RGC death rate that is negatively correlated with retinal levels of trkB FL protein and phosphorylated (activated) trkB FL . Depletion of target-derived trkB ligands by injection of trkB-Fc fusion protein into the superior colliculus increases the peak rate of RGC death compared with trkA-Fc-treated and normal animals. Adult trkB FL ϩ/Ϫ mice have a normal number of RGCs, despite an elevated peak death rate of immature RGCs. Thus, target-derived BDNF modulates the dynamics of developmental RGC death through trkB FL activation, but BDNF/trkB-independent mechanisms determine the final number of RGCs.
Introduction
An unresolved issue in CNS development concerns the role of target-derived neurotrophins, signaling through their cognate trk receptors and the p75 receptor, as modulators of developmental cell death. Within the peripheral nervous system, immature sensory and sympathetic neurons survive by competing for target-derived neurotrophins (Oppenheim, 1991; Lewin and Barde, 1996; Bibel and Barde, 2000) . Few defects have been detected in the CNS of mice with null mutations of single genes for neurotrophins or their receptors. In BDNF and trkB null mutants, the rate of developmental retinal ganglion cell (RGC) death [by an apoptotic process (Rehen and Linden, 1994) ] is unknown, but there is no effect on the final number of axons in the optic nerve (Cellerino et al., 1997; Rohrer et al., 2001) , which reflects the number of RGCs (Williams et al., 1986) . BDNF null mutants exhibit deficits in the differentiation of interneurons (Jones et al., 1994) , the maturation of Purkinje cell dendrites (Schwartz et al., 1997) , and the myelination of optic nerve axons (Cellerino et al., 1997) . In trkB null mutants, there are small increases in hippocampal and cerebellar granule cell death rate assayed at selected time points (Alcantara et al., 1997; Minichiello and Klein, 1996) .
In vitro, BDNF supports the survival of RGCs (Johnson et al., 1986; Thanos et al., 1988; Castillo et al., 1994) and many other central neurons, including basal forebrain cholinergic neurons, cortical neurons, hippocampal neurons, nigral dopaminergic neurons, and motor neurons (Korsching, 1993; Ghosh et al., 1994) . There is limited evidence, however, that endogenous, target-derived neurotrophins modulate normal developmental death among immature central neurons (von Bartheld and Johnson, 2001 ).
The spatial and temporal patterns of neurotrophin and trk receptor expression are consistent with a death-inhibiting action of endogenous neurotrophins on RGCs: trkA, trkB, and trkC are expressed in developing rodent RGCs (Ernfors et al., 1992; Zanellato et al., 1993; Koide et al., 1995; Rickman and Brecha, 1995; Ugolini et al., 1995) . TrkB is also expressed in mature rodent (Jelsma et al., 1993; Suzuki et al., 1998) and developing ferret (Allendoerfer et al., 1994) RGCs. Immature chick and Xenopus RGCs express trkB and trkC (Rodriguez-Tebar et al., 1993; Cohen-Cory and Fraser, 1994; Escandon et al., 1994; Okazawa et al., 1994; Garner et al., 1996; Hallbook et al., 1996) . In the developing rodent SC, BDNF protein is elevated during the interval when RGCs are eliminated and subsequently falls . Similarly, in the chick tectum, BDNF protein concentrations increase from embryonic day 4 through hatching (Johnson et al., 2003) ; this epoch includes the period when developmental RGC death is maximal. BDNF is present in the mature rodent superior colliculus (SC) (Hofer et al., 1990; Wetmore et al., 1990 ;
Materials and Methods
Materials. The trkA-Fc and trkB-Fc receptor bodies are fusion proteins consisting of two trkA (or trkB) extracellular domains in tandem with an Fc fragment (Shelton et al., 1995) . They were gifts of Genentech, Inc. (San Francisco, CA). The rabbit polyclonal anti-pan-trk antibody, which recognizes an epitope on the cytoplasmic domain common to all full-length trk receptors, was a gift from Dr. David Ginty (Johns Hopkins Medical Institute, Baltimore, MD). The rabbit polyclonal antibody against phosphorylated trk receptors [(anti-Ptrk) which recognizes phosphorylated tyr 490 within the Shc recognition motif of trkA, -B, and -C] and the mouse monoclonal (IgG1) antibody against the extracellular domain of the trkB receptor were purchased from Cell Signaling Technologies (Beverly, MA) and Transduction Laboratories (Lexington, KY), respectively. Chemiluminescent substrate (ECL) and high-range molecular weight markers were purchased from Amersham Biosciences (Piscataway, NJ). Platinum Taq Polymerase was purchased from Invitrogen (Gaithersburg, MD). Anti-mouse IgG peroxidase-conjugated antibody and other reagents were purchased from Sigma (St. Louis, MO).
Subjects and surgery. 129/C57BL/6 mice (mus musculus) and Syrian golden hamsters (Mesocricetus auratus) were subjects in this study. Mice with null mutations of BDNF and NT4 (Conover et al., 1995) were a gift of Regeneron Pharmaceuticals. Mice with null mutations of the trkB catalytic domain (Klein et al., 1993) were purchased from Jackson Laboratories (Bar Harbor ME; catalog #003098). Hamsters were purchased from Charles River. Because the 129 mouse lines used to make the 129/ C57BL/6 hybrids differed between the Regeneron mice and the Jackson Laboratories mice, separate wild-type (WT) control groups were studied for comparison with the respective mutant lines. In rodents, because virtually all RGCs project to the SC (Linden and Esberard, 1987) , RGC nuclei can be selectively labeled by retrograde transport of intracollicularly injected diamidino yellow (DY) (Keizer et al., 1983) . Thus neonatal mice and hamsters were anesthetized by hypothermia, the scalp was incised, a glass pipette (tip diameter 50 m) was lowered through a small hole in the skull, and 0.1 l of DY (2% in H 2 O) was injected bilaterally at a site near the center of the SC and 400 m deep to the dorsal surface. Each injection was made over 2 min using a Picospritzer. At the end of each injection, the pipette was left in situ for 2 min before being withdrawn slowly, to minimize reflux. The scalp was sutured shut, and the animals were reanimated and returned to their mothers.
Previous studies differ as to whether the peak of murine RGC death occurs on postnatal (P) day 2 (first 24 hr after birth ϭ P0) (Young, 1984) or P6 (Linden and Pinto, 1985; Williams et al., 1996) . Therefore, we determined the frequency of pyknotic RGCs on P2 and P6 in mice that were treated with DY, as above, on P1 and P2, respectively. Hamsters were treated with DY on P1, and the rate of developmental RGC death was determined on the day of its normal maximum, P4 (Sengelaub et al., 1986) . We demonstrated previously that intracollicular BDNF injections on P3 significantly reduce RGC death at 20 hr latency, on P4 (Ma et al., 1998) . Therefore, on P3, 20 hr before being killed on P4, DY-injected hamsters were anesthetized by Halothane inhalation (0.5-1.5% in O 2 ). TrkB-Fc (Shelton et al., 1995) (18.7 M in 0.1% BSA in PBS; 1 l per SC) or, as a control, trkA-Fc (Shelton et al., 1995) (18.7 M in 0.1% BSA in PBS; 1 l per SC) was pressure injected bilaterally into the SC (three sites per SC spaced equidistantly from each other and from the border of the SC and 400 m deep to the dorsal surface). This procedure assured that the axons of both ipsilaterally and contralaterally projecting RGCs were exposed to receptor bodies. Additional DY-treated hamsters were killed on P4 without fusion protein treatment.
Quantitative analysis of the rate of RGC pyknosis. All animals were given an overdose of Nembutal anesthesia (intraperitoneally) and perfused transcardially with 4% (w/v) paraformaldehyde in PO 4 buffer (0.1 M, pH 7.4). Their eyes were enucleated, the cornea, iris, lens, and vitreous were rapidly removed from each eye, and the retina was dissected from the eye cup in cold PO 4 buffer (0.1 M, pH 7.4, 4°C). Four relieving cuts were made along radii lying at 45°angles to the principal axes of the retina. The retinas were whole mounted, vitreal side up, on squares of black nitrocellulose paper, placed on a glass slide, and coverslipped with glycerolgelatin. Some WT mouse retinas were stained after dissection with Hoechst dye (0.1 mg/100 ml; 3 hr, room temperature) and rinsed in PBS before they were mounted on nitrocellulose paper.
The retinas of all DY-treated animals were initially surveyed to verify that RGC nuclei were uniformly labeled across the retina. Retinas not meeting this criterion were discarded. To avoid any bias in the results, we used a blind data collection technique: all retinas used for nuclear counts were coded so that the persons doing the counting did not know the treatment history or genotype of the animals from which the retinas were obtained; no results were revealed to the counters until the completion of data collection for the entire study.
Using a computer-assisted fluorescent microscope system (Neurotrace) equipped with a 100ϫ oil immersion objective and an ultraviolet filter set, we counted the number of healthy (chromatin not clumped) (Fig. 1) nuclei and the number of pyknotic (clumped chromatin) (Fig. 1 ) nuclei in a square sampling region within each quadrant. Previous studies have shown that there is a 1:1 correspondence between DY-labeled pyknotic nuclei and pyknotic nuclei labeled by Nissl stains (Harvey et al., 1990) . Healthy and pyknotic RGC nuclei have the same respective appearances in WT and mutant mice (Fig. 1) . Because retinal surface areas in hamsters are bigger than in mice, sampling regions of different size were used. For hamsters, sampling regions were each 57,600 m 2 and centered ϳ0.92 mm from the optic disc along radii directed toward the dorsal, ventral, temporal, and nasal poles of the eye. For mice, sampling regions were each 44,100 m 2 and centered ϳ0.77 mm from the optic disc. For each sampling region (or for all four sampling regions pooled together), the number of pyknotic nuclei is divided by the total number of nuclei (healthy plus pyknotic) to obtain the fraction of RGCs that are pyknotic. This index is a linear measure of the rate of RGC death and is more reliable than counts of the total number of pyknotic nuclei for which there is significantly more interanimal variability (Harvey et al., 1990; Harvey and Robertson, 1992; Ma et al., 1998) . Different experimental groups were compared with respect to the frequency of pyknotic nuclei using the Mann-Whitney U test (two-tailed). To assure consistency among observers in their criteria for identifying normal and pyknotic RGCs, retinas were randomly selected and recounted blind by a different observer at the completion of the study. The fractions of pyknotic RGCs obtained by different observers fell within 4% of each other.
Determination of mouse genotype. Mice were overdosed with Nembutal. Just before perfusion, the tail and one hindleg were removed to obtain tissue for DNA extraction using QIAamp DNA mini kits (Qiagen Inc., Valencia, CA) following the manufacturer's procedures. PCR amplification of DNA coding trkB FL , BDNF, and NT4 was performed using protocols supplied by the Jackson Laboratory. For amplification of DNA coding trkB FL, the oligonucleotide primers (one 5Ј primer for WT, one for mutant trkB FL , and a common 3Ј primer) contained the following sequences: primer 1: 5Ј-TCGCGTAAAGACGGAACATGATCC-3Ј; primer 2: 5Ј-AG-ACCATGATGAGTGGGTCGC-3Ј; primer 3: 5Ј-GATGTGGAATGTGT-GCGAGGC-3Ј.
PCR was run under the following conditions: 1.0 l DNA (1 mg/ml), 0.5 l of each oligonucleotide (0.5 M), 0.5 l Platinum Taq Polymerase, MgCl 2 (1.5 mM), and dNTP mix (0.2 mM) in a total volume of 50 l; denature 1 min at 94°C; anneal 30 sec at 65°C, and extend 1 min at 72°C. The reaction was repeated for 40 cycles. For amplification of DNA coding BDNF and NT4, the oligonucleotide primers contained the following sequences: BDNF, primer 1, 5Ј-CATACTTCGGTTGCATG-3Ј, primer 2, 5Ј-ACTGTCACACACGCTCA-3Ј, primer 3, 5Ј-ATGGAAGGATTGGAG-CTA-3Ј; NT4, primer 1, 5Ј-GATCGTATGCGACGCAGTGAGT-3Ј, primer 2, 5Ј-GATCGACTGCTTAGCCTTGCAT-3Ј, primer 3, 5Ј-CACCAAAGA-ACGGAGCCGGTT-3Ј.
For amplification of DNA coding BDNF, the PCR was run as follows: 2.0 l DNA (1 mg/ml), 0.9 l (0.5 M) of each primer, 0.06 l Platinum Taq Polymerase, MgCl 2 (2.5 mM), and dNTP mix (0.24 mM) in a total volume of 22 l: denature 1 min at 94°C; anneal 2 min at 57°C, and extend 5 min at 72°C (1 cycle); denature 1.5 min at 94°C; anneal 2 min at 57°C, and extend 3 min at 72°C (40 cycles). For amplification of DNA coding NT4, the PCR was run as follows: 2.0 l DNA (1 mg/ml), 0.9 l (0.5 M) of each primer, 0.06 l Platinum Taq Polymerase, MgCl 2 (2.4 mM), and dNTP mix (0.24 mM) in a total volume of 20 l: denature 1 min at 94°C; anneal 2 min at 58°C, and extend 5 min @ 72°C (1 cycle); denature 1.5 min at 94°C; anneal 2 min at 58°C, and extend 3 min at 72°C (40 cycles). All reaction products were electrophoresed on a 1.0% agarose gel.
The 900 and 1000 bp amplicons identified the WT and mutated trkB FL alleles, respectively. The 400 and 200 bp amplicons identified the WT and mutated BDNF alleles, respectively. The 238 and 320 bp amplicons identified the WT and mutated NT4 alleles, respectively.
Immunoprecipitation and Western blot analysis. Mice were killed by decapitation on P2. The retinas were dissected from the eye cups in cold PO 4 buffer (0.1 M, pH 7.4, 4°C), and dissected tissue was frozen on dry ice. Retinas were pooled to obtain independent samples of sufficient size for analysis (one sample from 12 retinas of six animals) and homogenized and lysed in nondenaturing buffer [20 mM Tris, pH 8.0, 137 mM NaCl, 1% (w/v) Nonidet P-40, 10% (v/v) glycerol containing 1 g/ml leupeptin, 1 mM phenylmethylsulfonylfluoride (PMSF), 10 g/ml aprotinin, and 0.5 mM sodium orthovanadate]. Separate aliquots of each lysate (1 ml, 1 mg total protein) were immunoprecipitated using either 5 l anti-pan-trk serum or 5 l anti-Ptrk antibody (0.2 mg/ml) while they were rotated overnight at 4°C to capture trk receptors or phosphorylated trk receptors, respectively. After this, 60 l of a 50% suspension of protein A agarose beads was added to each sample, and samples were rotated at 4°C for 2 hr. Sample pellets containing the immunocomplexes were washed three times in lysis buffer and once in ddH 2 O. After the final wash, pellets were resuspended in 25 l of sample buffer [62.5 mM Tris HCl, pH 6.8, 2% (v/v) SDS, 10% (v/v) glycerol, 5% (v/v) ␤-mercaptoethanol and 0.004% (w/v) bromophenol blue], boiled for 5 min, electrophoresed on a 7.5% polyacrylamide gel, and transferred to a nitrocellulose membrane (0.4 m pore size). Pan-trk and Ptrk immunoprecipitates from the same sample of lysate were loaded into adjacent lanes on the gels. Each gel contained pan-trk and Ptrk immunoprecipitation (IP) products from the same number of samples of lysate from each genotype. Membranes were incubated with anti-trkB (1:500 dilution) overnight at 4°C, washed, incubated with anti-mouse IgG peroxidase-conjugated antibody (1:2500 dilution), washed, and treated with ECL reagents (Amersham Biosciences) per the manufacturer's instructions. The ECL-treated membranes were placed in contact with blue-sensitive x-ray film (Molecular Technologies, St. Louis, MO), which when developed was scanned and processed for analysis using a densitometer (Molecular Dynamics; Personal Densitometer SI). Average pixel intensities of protein bands were measured and analyzed using Molecular Dynamics Imagequant, version 5.0 for Windows, and background pixel intensities were subtracted from protein band intensities to obtain corrected band intensities.
The statistical significance of genotype-associated, quantitative differences in the levels of trkB FL and phosphorylated trkB FL (PtrkB FL ) was assessed using the Wilcoxon signed-rank test. The significance of genotype-associated differences in the ratio of the PtrkB FL and trkB FL signals (an index of the fraction of trkB FL that is phosphorylated) was assessed using a Mann-Whitney U test (two-tailed).
In control experiments, we demonstrated that our immunoprecipitation-Western blot procedure is linear over the range of signal intensities detected in these studies. Additional aliquots of lysate were prepared from WT mice and serially diluted by a factor of two at each dilution. Full-strength and diluted lysates were then immunoprecipitated using the pan-trk or Ptrk antibodies. Immunoprecipitation products obtained from different concentrations of the same lysate were then run on adjoining lanes on the same gel, and the intensity of the trkB FL and PtrkB FL signals was determined as above. The results (data not shown) demonstrate that for both trkB FL and PtrkB FL , signal intensity is linear over at least a fourfold range of lysate dilution, whereas the signals measured in our experimental animals differed from those in normal WT mice only by a factor of 2, within the linear range of the assay (see Results).
Electron microscopy. The details of our procedures have been described previously (Williams et al., 1996) and are summarized here. Mice (see Table 1 ) were anesthetized with Avertin and perfused transcardially with 0.9% saline followed by glutaraldehyde/paraformaldehyde fixative. After postfixation, the optic nerves were dissected, osmicated, embedded, and sectioned at a standard distance from the optic disc. An unbiased sampling procedure was used to determine the number of axons in each optic nerve. The effects of genotype, sex, age, brain weight, and body weight on the number of optic nerve axons were determined using a multiple linear regression model. The significance of differences between WT and trkB FL ϩ/Ϫ mice with respect to the number of optic nerve axons was assessed using a two-tailed t test.
These experiments were conducted in accordance with National Institutes of Health guidelines regarding the care and use of animals for experimental procedures.
Results

Endogenous BDNF but not NT4 reduces the rate of developmental RGC death
We examined the roles of BDNF and NT4 in modulating the rate of developmental RGC death by investigating the effects of null mutation of each ligand individually and of both together. On P2, there is no significant difference in the frequency of pyknotic RGC nuclei in WT (0.96 Ϯ 0.11%) and BDNF ϩ/ϩ NT4 Ϫ/Ϫ (1.04 Ϯ 0.21%) mice ( p ϭ 0.4624) (Fig. 2) . In BDNF ϩ/Ϫ NT4 ϩ/ϩ and BDNF Ϫ/Ϫ NT4 Ϫ/Ϫ mice, respectively, the frequencies of pyknotic RGCs are 1.4-fold (1.31 Ϯ 0.06%; p ϭ 0.0143) and 1.7-fold (1.62 Ϯ 0.35%; p ϭ 0.009) that in WT mice (Fig. 2) . Our data exclude the possibility that NT4 enhances the effects of BDNF on RGC death. If this were the case, one would expect that BDNF Ϫ/Ϫ mice would have an effect on RGC death greater than or equal to that in BDNF ϩ/Ϫ mice but a smaller effect than that in
There is no statistically significant difference between BDNF ϩ/Ϫ NT4 ϩ/ϩ mice and BDNF Ϫ/Ϫ NT4 Ϫ/Ϫ mice ( p ϭ 0.0854). Thus the effect of BDNF null mutation on RGC death is saturated, or almost so, in BDNF(ϩ/Ϫ) mice, and additional null mutation of NT4 does not significantly enhance the effect. These data demonstrate that endogenous BDNF but not NT4, reduces the rate of developmental RGC death in vivo.
TrkB FL receptor expression has a graded effect on developmental RGC death Examination of the effects of null mutation of the trkB catalytic domain tests the hypothesis that trkB FL receptor signaling modulates the rate of developmental RGC death. In WT mice, the frequency of pyknotic RGC nuclei falls from 0.87 Ϯ 0.18% on P2 to 0.15 Ϯ 0.04% on P6 (Fig. 3) . On P2, in trkB FL ϩ/Ϫ and trkB FL Ϫ/Ϫ mice, respectively, the frequency of pyknotic RGCs is increased 1.5-fold (1.30 Ϯ 0.21%; p ϭ 0.039) and 2.2-fold (1.92 Ϯ 0.23%; p ϭ 0.0105) as compared with WT mice (Fig. 3) . On P6, in trkB FL ϩ/Ϫ and trkB FL Ϫ/Ϫ mice, respectively, the frequency of pyknotic RGCs is elevated 4.5-fold (0.68 Ϯ 0.15%; p ϭ 0.0105) and 7.4-fold (1.11 Ϯ 0.07%; p ϭ 0.008), as compared with WT mice (Fig. 3) . At both ages, the frequency of pyknotic RGCs is greater in homozygous than in heterozygous mutants ( Fig. 3) ( p ϭ 0.0105 on P2; p ϭ 0.004 on P6). In all three genotypes, the frequency of pyknotic RGCs is greater on P2 than on P6, and the slopes of the plots of pyknotic RGC frequency as a function of age are similar among genotypes (WT ϭ Ϫ0.180% per day; trkB FL ϩ/Ϫ ϭ Ϫ0.155% per day; trkB FL Ϫ/Ϫ ϭ Ϫ0.203% per day). Thus, on P2 and P6, null mutation of the trkB FL catalytic domain causes a dose-dependent increase in the rate of RGC death. This suggests that in vivo, trkB FL receptor signaling modulates the rate of developmental RGC death; however, at least between P2 and P6, the mutation does not alter the time constant of the developmental change in the rate of RGC death.
Null mutation of trkB FL causes dose-dependent reductions in retinal trkB FL protein and trkB phosphorylation
If trkB FL signaling modulates the rate of developmental RGC death, then null mutations of the trkB FL gene should also have a dose-dependent effect on the activation of trkB FL , as indicated by the amount of PtrkB FL . We measured the levels of trkB FL protein and PtrkB FL protein in WT, trkB FL ϩ/Ϫ , and trkB FL Ϫ/Ϫ mice to determine whether this is the case.
Retinal tissue lysates from all three genotypes of mice were prepared, immunoprecipitated, and subjected to Western blot analysis, as described in Materials and Methods (Fig. 4 A) . There is a dose-dependent effect of the mutant gene on the retinal concentration of trkB FL protein (Fig. 4 B) . In trkB FL ϩ/Ϫ mice, the tissue concentration of trkB FL in the retinas is 51% of that in WT ( p ϭ 0.0277). There was no detectable trkB FL in the retinas of trkB FL Ϫ/Ϫ mice. The retinal level of PtrkB FL is reduced to 70% of its normal value in the retinas of trkB FL ϩ/Ϫ mice ( Fig. 4C ) ( p ϭ 0.0277), whereas there is no detectable PtrkB FL in the retinas of trkB FL Ϫ/Ϫ mice. In the retinas of WT mice (Fig. 4 D) , the PtrkB FL / trkB FL signal ratio, a linear index of the fraction of trkB FL that is phosphorylated, is 0.39 Ϯ 0.13. In the retinas of trkB FL ϩ/Ϫ mice, the PtrkB FL /trkB FL signal ratio is increased to 0.55 Ϯ 0.06 (Fig.  4 D) ( p ϭ 0.0446). The relative amount of trkB FL phosphorylation increases in trkB FL ϩ/Ϫ mice because the decrease in trkB FL is relatively greater than the decrease in PtrkB FL . The absence of a detectable band at 145 kDa for both pan-trk and Ptrk IP products from lysates obtained from trkB FL Ϫ/Ϫ mice demonstrates that the trkB antibody does not cross-react with retinal trkA or trkC.
Our data show that null mutation of the trkB FL catalytic domain produces dose-dependent reductions in the absolute amounts of retinal trkB FL and PtrkB FL . These changes are negatively correlated with the dose-dependent increases in the rate of RGC death in trkB FL mutant mice.
Depletion of endogenous trkB ligands in the SC during the normal period of developmental RGC elimination increases the rate of RGC death
TrkB-Fc injected into the SC depletes trkB ligands only at the injection site and for a limited time after treatment. Thus, intracollicular receptor body injection can be used to determine the role of endogenous, target-derived trkB ligands in modulating the rate of developmental RGC death. We examined the effects of intra-SC trkB-Fc injection at 20 hr after treatment because previous studies (Ma et al., 1998) have shown that this is a latency at which increased BDNF/trkB signaling has an effect on the rate of RGC death. Twenty hours after injection of trkB-Fc, the frequency of DY-labeled, pyknotic RGC nuclei (1.7 Ϯ 0.34%) is 1.5- and 1.7-fold higher, respectively, than in trkA-Fc-injected (1.12 Ϯ 0.22%; p ϭ 0.004) or untreated (1.03 Ϯ 0.3%; p ϭ 0.019) hamsters (Fig. 5). [These experiments were performed immediately after our original pharmacologic studies of the effects of exogenous BDNF (Ma et al., 1998) and thus used the same species, Mesocricetus auratus, the Syrian golden hamster. Mice were used in the other experiments of the present study because of the availability of signaling mutants. The trkB-Fc reagent is no longer available, so the experiments cannot be repeated in mice. There is no reason to believe that the results in mice would be any different.] The absence of a significant difference between trkA-Fctreated and untreated hamsters ( p ϭ 0.437) demonstrates that (1) the effects of trkB-Fc are specific and cannot be attributed to all extracellular trk domains or to the Fc fragment of the fusion protein and (2) the injection procedure did not cause lesion-induced RGC pyknosis. Our data demonstrate that endogenous, target-derived trkB ligands reduce the rate of developmental RGC death.
DY injection into the SC does not induce RGC death
Intra-SC injection of DY could produce SC lesions or a toxic accumulation of DY in RGCs, either of which could elevate the rate of RGC death. If this were the case, it would be uncertain whether BDNF/trkB signaling modulates developmentally induced, lesion-induced, or toxicityinduced RGC death. To control for these possibilities, we treated WT mice with DY on P1 and killed them on P2, as above. There is no significant difference between untreated (n ϭ 6) and DY-treated (n ϭ 4) mice with respect to the frequency of pyknotic nuclei in the RGC layer, as revealed by Hoechst staining ( p ϭ 0.89) (Fig. 6) . The possibility that RGC death is induced by DY injections in our mice treated and killed on P2 and P6, respectively, is excluded by our previous data (Ma et al., 1998) showing no effect of intra-SC DY injection on RGC death up to at least 3 d after injection and by results in cats (Innocenti, 1981) that demonstrate the viability of cortical neurons over many weeks after neonatal DY labeling. Thus our data demonstrate the effects of BDNF/trkB signaling on developmentally, not lesion-induced or DY toxicity-induced, RGC death.
Reduced trkB FL signaling does not alter the number of RGCs in mature mice
The final number of RGCs is equal to the number produced less the number that die during development (equal to the integral of the rate of RGC death as a function of time). Thus the rate of RGC death at any particular age(s) does not necessarily predict the net amount of cell death or the final number of RGCs. Because the number of axons in the optic nerve is an accurate indicator of the number of RGCs (Williams et al., 1986) , we assessed the effect of trkB signaling on the final number of RGCs by counting the number of axons in the optic nerves of mature WT and trkB FL ϩ/Ϫ mice (Table 1) . There is no significant difference between the number of axons in the optic nerves of WT mice (63,322 Ϯ 4196) and the number of axons in the optic nerves of trkB FL ϩ/Ϫ mice (67,654 Ϯ 6394; p ϭ 0.17), although, as shown above in neonatal trkB FL ϩ/Ϫ mice, the rate of RGC death is elevated compared with normal, and retinal trkB FL phosphorylation is reduced.
We did not examine the number of optic nerve axons in trk-B FL Ϫ/Ϫ mice because of potential interpretative difficulties.
(1) If the number of axons were reduced, this might be attributed to the poor health status of trkB FL Ϫ/Ϫ mice, because they waste and die by approximately P14. TrkB FL ϩ/Ϫ mice thrive and grow normally and have a normal life span. (2) If there were no change in the number of optic nerve axons, it could be hypothesized that had the trkB FL Ϫ/Ϫ mice lived longer, the number of axons might subsequently have decreased.
Discussion
Endogenous, target-derived BDNF signaling through trkB FL alters the dynamics of developmental RGC death in vivo The survival-promoting role of target-derived neurotrophins during normal development is well established for peripheral neurons (Oppenheim, 1991; Lewin and Barde, 1996) but is controversial for central neurons. The best documented example for central neurons is the effect of endogenous retinal BDNF on chick isthmo-optic neurons (von Bartheld and Johnson, 2001) . TrkB signaling may regulate the death rate of immature geniculocortical neurons (Lotto et al., 2001 ). The dramatic reduction in the rate of developmental RGC death after intra-SC injection of BDNF (Ma et al., 1998) suggests that endogenous BDNF within the SC might inhibit the death of immature RGCs.
Here we examine the effects in developing RGCs of the two high-affinity trkB receptor ligands, BDNF and NT4. Null mutation of BDNF (alone or in combination with NT4), but not mutation of NT4 alone, increases the rate of developmental RGC death. Thus endogenous BDNF, but not NT4, reduces the rate of RGC death during normal development. We also determined that null mutation of the catalytic domain of trkB FL induces dosedependent increases in the rate of developmental RGC death on P2 and P6 and reductions in the level of PtrkB FL in the retina.
Because heterozygous null mutation of BDNF or trkB FL increases the rate of RGC death on P2 and P6 without changing the final number of RGCs, the rate of RGC death should be subnormal at other ages, most likely shortening the epoch of RGC death. These effects show that BDNF, signaling through trkB FL in RGCs, modulates the dynamics of developmental RGC death. P75 neurotrophin receptor mutation can also alter the dynamics of neuronal death (Bamji et al., 1998) .
Because all cells in constitutive "knock-out" mice are affected by the mutation throughout life, data from those animals alone do not indicate at which site(s) or developmental stage(s) the mutation exerts its effect. When and on what cells do targetderived trkB ligands act to modulate the rate of RGC death at the developmental stages examined in this study? Several observations suggest that during the developmental epoch when RGCs are eliminated, target-derived BDNF, binding to trkB receptors on RGC axon terminals, reduces the death rate of immature RGCs.
(1) Depletion of trkB ligands by intra-SC injection of trkB-Fc receptor bodies increases the rate of developmental RGC death. The binding of trkB-Fc receptor bodies to trkB ligands is spatially restricted to the region of the injection and temporally restricted to a limited epoch beginning at the time of injection.
(2) Intracerebral injection of trkB-Fc dramatically reduces trk phosphorylation at the injection site (Cabelli et al., 1997) . Because trkA-Fc and trkB-Fc have the same specificity of binding to different neurotrophins as their respective native receptors (Shelton et al., 1995) , the reduced phosphorylation demonstrates the binding of trkB ligands by trkB-Fc in vivo. (3) BDNF injected into the SC does not reduce the rate of developmental RGC death until after the injected BDNF accumulates in the retina (Ma et al., 1998) , although intracellular messengers, notably PtrkB FL in signaling endosomes (Bhattacharyya et al., 1997; Watson et al., 1999) that are activated when BDNF binds to its receptors on RGC axon terminals, are probably cotransported to the retina with BDNF. Similarly, intra-ocularly injected BDNF acts with a delay to reduce the rate of developmental death of chick isthmooptic neurons (Primi and Clarke, 1996) .
TrkB activation drops within a few hours when ligand is withdrawn in vitro and probably responds more rapidly in vivo (Knü-sel et al., 1997) ; however, the fall in trkB activation induced by a single intra-SC injection of trkB-Fc, although rapid, is probably transient. Thus, the trkB-Fc-induced increase in RGC death rate may also be transient and may return to normal along a curve that parallels the recovery of trkB activation but is delayed by 12-20 hr, the latency required for increased BDNF/trkB signaling to reduce the RGC death rate (Ma et al., 1998) . At the 20 hr latency of this study, the RGC death rate may already have begun to fall. Thus, the 50 -70% death rate increase induced by trkB-Fc is a minimum estimate of the effect of endogenous, target-derived trkB ligands.
Our data do not necessarily indicate that BDNF is the only target-derived factor that reduces the rate of developmental RGC death. Other neurotrophic factors that elevate intracellular cAMP levels may act synergistically with BDNF (Meyer-Franke et al., 1995) . The action of multiple such target-derived factors may explain why the rate of RGC death is only 2.2-7.4ϫ the normal rate in trkB FL Ϫ/Ϫ mice and only 1.7ϫ the normal rate after intracollicular injection of trkB-Fc, although on a molar basis, the tissue concentration of trkB-Fc (ϳ1000-fold that of endogenous trkB) (Rodriguez-Tebar and Barde, 1988) was adequate to block the binding of trkB ligands to endogenous trkB receptors. An alternative explanation of why the effects of trkB-Fc treatment were not greater, that endogenous trkB might have a much greater affinity for its ligands than trkB-Fc, has been excluded previously (Shelton et al., 1995) . Because trkB mRNA and protein are expressed in the rodent SC (Altar et al., 1994; Yan et al., 1997 ; our study), depletion of intra-SC BDNF might also act by reducing either (1) the secretion by SC cells of other factors that slow the rate of RGC death or (2) the density of receptors for those factors on RGC axon terminals (Wyatt and Davies, 1993) . The effects of trkB-Fc injection render extremely unlikely the possibility that a reduced rate of clearance of pyknotic nuclei contributes to the increased frequency of pyknotic RGCs in mice with null mutations of BDNF or trkB FL . Intra-SC injection of trkB-Fc causes similar increases in the frequency of pyknotic RGC nuclei but cannot affect the clearance of pyknotic debris by phagocytes in the retina, from which the injection site is effectively isolated. Thus, null mutation-induced increases in the frequency of pyknotic nuclei are caused by increases in the rate of RGC death.
Several observations exclude the possibility that the elevated RGC death rate in mice with null mutations of BDNF or trkB FL is caused by malnutrition or other nonspecific effects rather than by the direct effects of BDNF/trkB FL signaling on RGCs.
(1) Mice that are heterozygous for null mutations of BDNF or trkB FL gain weight normally, have a normal life span, and have elevated rates of developmental RGC death. (2) The final number of RGCs is normal in mice with null mutations of BDNF (Cellerino et al., 1997) or trkB (Rohrer et al., 2001 ; our study), despite the elevated RGC death rate earlier in life. (3) Although homozygous mutants for BDNF and trkB FL waste and die during the second or third postnatal week, these animals have elevated rates of RGC death as early as P2, before wasting occurs.
It is unlikely that the elevated RGC death rate in mice with null mutations of trkB FL or BDNF is caused by mutation-induced increases in RGC proliferation before the period of RGC death.
(1) BDNF/trkB FL signaling is mitogenic (Represa et al., 1993; Zigova et al., 1998) . Thus, if proliferation is abnormal in null mutants, it is likely to be reduced. (2) TrkB-Fc treatment of hamsters on P3, after RGC proliferation has terminated (embryonic day 11) (Sengelaub et al., 1986) , causes increases in the RGC death rate comparable with those induced by null mutation of BDNF or trkB FL .
Mechanisms of the effects of BDNF/trkB FL on RGC death dynamics
Ligand binding to trkB FL exerts its effects by trkB FL autophosphorylation and subsequent activation of at least two intracellular signaling pathways (Atwal et al., 2000; Miller, 1997, 2000) . As the dosage of mutant trkB FL increases, the accompanying increase in RGC death and decrease in trkB FL activation in the retina (assessed in phosphorylation assays) provide evidence for the modulation of RGC death rate by activated trkB FL receptors transported to RGC somata from RGC axon terminals in the SC. Because the molar tissue concentration of trkB exceeds by several orders of magnitude that of BDNF (Rodriguez-Tebar and Barde, 1988) , it is surprising that trkB FL phosphorylation is diminished (by 30%) in the retinas of trkB FL ϩ/Ϫ mice, in which trkB FL is reduced by only 49%. Reductions in (1) the ratio of trkB FL to truncated trkB (trkB T ), which lacks a catalytic domain, or (2) the retrograde transport of BDNF/PtrkB FL complexes from RGC axon terminals to somata are possible explanations.
Dynamics of RGC death are BDNF/trkB FL dependent, whereas RGC number is not On P2 and P6, null mutation of trkB FL alone or BDNF (alone or in combination with NT4) increases the rate of developmental RGC death; however, null mutation of trkB FL alone (present results) or in combination with trkB T (Rohrer et al., 2001 ), or of BDNF alone (Cellerino et al., 1997) , does not alter the final number of RGCs that remain after RGC death is complete. Thus the cellular mechanisms controlling the dynamics of developmental RGC death are BDNF/trkB-dependent, whereas those that regulate the final number of RGCs are BDNF/trkB independent. The Pearl mutation (Williams et al., 1990 ) also alters the dynamics of RGC death but not the final RGC number; this is difficult to interpret because the action of the gene product is unknown.
In studies of the mechanisms of developmental or injuryrelated cell death, it is often assumed that various measures of the rate of cell death are accurate indicators of the final number of neurons that will remain after cell death ceases. At least with respect to the actions of BDNF/trkB FL on developing RGCs, this is not true. This is significant for the design and interpretation of functional studies of neurotrophic factors. In assessing the neurotrophic actions of extracellular molecules on a target cell population, one must distinguish between effects on the dynamics of cell elimination and on aggregate cell death-survival.
